A subgroup analysis of the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial showed that patients with all stroke subtypes derived a clinical benefit from thrombolytic treatment. 1 Even in patients who were classified as having small vessel disease according to the Trial of Org 10172 in Acute Treatment (TOAST) criteria, thrombolysis improved the outcome. However, the demonstration of an arterial occlusion was not mandatory in NINDS. Therefore, the question whether acute stroke patients without arterial occlusion should be treated with thrombolysis has not been resolved yet. 2, 3 The answer depends mainly on the spontaneous course of such patients. For this reason, we analyzed our acute stroke patients who underwent arteriography with the intention to perform intraarterial thrombolysis (IAT) but who did not show any occluded vessel and therefore were not treated. The aim was to determine their clinical and radiological outcome and to identify predictors of clinical outcome.
Subjects and Methods
From January 1998 to December 2002, 283 patients with acute cerebral ischemia met our institutional criteria for IAT and therefore underwent cerebral arteriography immediately after clinical evaluation and computerized tomography (CT) or magnetic resonance imaging (MRI). The indications for IAT have been published previously. 4 Eventually, 191 patients with occlusions of intracranial vessels correlating to the clinical signs underwent IAT. In 92 (33%) patients, IAT was not performed for the following reasons: occlusion of small branches only of the middle cerebral artery (MCA) or the posterior cerebral artery (nϭ7 or nϭ1, respectively); extracranial carotid artery occlusion or high-grade stenosis (nϭ49) or vertebral artery occlusion and contralateral vertebral hypoplasia (nϭ5) preventing access to the occluded intracranial artery; aortic dissection (nϭ2); and no visualization of any occlusion of an intracranial artery (nϭ28). Data of the latter 28 patients without intracranial vessel occlusion were analyzed and are the subject of this study. The neurological status was assessed after admission using the NIHSS score by a neurologist. 5 The clinical stroke subtypes were categorized according to the Oxfordshire Community Stroke Project (OCSP) classification. 6 All patients immediately underwent CT or MR scans after neurological evaluation to exclude intracerebral hemorrhage. Early parenchymal CT signs of ischemia were defined according to the criteria by von Kummer et al. 7 Arteriography was performed by transfemoral approach. All patients received a 4-vessel diagnostic arteriography to assess the complete vessel status and collateral circulation if present. Either a control CT (nϭ3) or control MRI (nϭ26) scan was performed 1 or 2 days after arteriography. CT or MRI lesions were classified similar to the criteria published by Mead et al 8 as follows: (1) large cortical MCA infarct (more than half of the MCA territory); (2) medium-sized or small anterior circulation infarct (less than half or the MCA territory or any of the ACA territory); (3) large (Ͼ1.5 cm) subcortical infarct (striatocapsular); (4) lacunar (Ͻ1.5 cm) anterior circulation infarct; (5) lacunar (Ͻ1.5 cm) posterior circulation infarct; and (6) nonlacunar posterior circulation infarct.
Stroke cause was determined using additional investigations as necessary and classified according to the TOAST criteria. 9 Outcome was assessed 3 months after the ictus by clinical examination using the modified Rankin scale (mRS). 10 The mRS scale scores of 0 to 2 were defined as "favorable" and mRS scores of 3 to 5 as "poor" outcome. Death corresponds to a mRS score of 6 
Results

Demographic, Clinical, and Radiological Data
Twenty-eight patients (21 men, 7 women) with a mean age of 58Ϯ12 (range 18 to 82) years who did not show any vessel occlusion on early arteriography were identified. The median baseline NIHSS on admission was 7 and ranged from 4 to 25. Clinical neurological examinations indicated a lacunar syndrome in 7 patients (25%), a partial anterior circulation syndrome in 15 (54%), and a posterior circulation syndrome in 6 patients (21%). No total anterior circulation syndrome was observed. The mean time from symptom onset to arteriography was 226 minutes (range 115 to 325 minutes). All but 1 admission CT was normal. Only 1 patient (4%) showed early parenchymal CT signs of ischemia, and other abnormalities such as hyperdense artery signs were not observed. Presumed stroke cause was cardiac embolism in 11 patients (39%), small artery disease in 6 (21%), iatrogenic after coronary angiography in 1 (4%), and undetermined in 10 patients (36%).
Radiological Outcome
On follow-up brain imaging, 8 patients (29%) showed a lacunar lesion, 2 (7%) had a striatocapsular infarct, 6 (21%) had a small-or medium-sized anterior circulation infarct, 2 (7%) had multiple anterior circulation infarcts, and 4 (14%) had multiple posterior circulation infarcts. In 5 patients (18%), follow-up MRI (nϭ4) or CT (nϭ1) did not reveal any ischemic lesion. One patient (4%) with rapid resolution of his clinical deficits had clinical but no imaging follow-up. Baseline data and clinical and radiological outcome of each patient are summarized in Table 1 .
Clinical Outcome
After 3 months, mRS was Յ2 in 21 patients (75%), indicating a favorable outcome. Six patients (21%) had a poor outcome (mRS 3 or 4). One patient (4%) had a myocardial infarction 1 day after his stroke and died. Before myocardial infarction, his NIHSS score was 8.
Predictors of Outcome
Age, sex, initial NIHSS score, clinical stroke syndrome, time to arteriography, stroke cause, early signs of ischemia on admission CT, and vascular risk factors failed to predict clinical outcome (Table 2 ).
Discussion
The outcome of 28 acute stroke patients with normal early arteriograms was favorable in 21 (75%). This is the main message of our study. Nevertheless, the majority (78%) has cerebral infarction according to brain imaging, and death or significant disability occurs in one quarter of the patients. Another small series of 10 patients without a visible clot on arteriography that was performed within 4 hours of symptom onset gave similar results. Eight of 10 follow-up brain scans showed a new cerebral infarct. 11 Four of these 10 patients (40%) were disabled (mRSϾ2) after 3 months. Good outcomes were also reported in 4 of 5 patients of another series who had been treated with IAT, even without visible occlusion on arteriography. 12 There may be 2 pathomechanisms leading to ischemic stroke and disability in patients with normal arteriography. First, occlusions of arterioles are not visualized on clinical arteriography. They may account for most of the lacunar infarcts. Second, an occlusion of a larger vessel may cause an ischemic stroke before it recanalizes spontaneously. Such a mechanism may be operative when collaterals are inadequate to preserve perfusion until recanalization occurs.
The question arises whether it is justified to exclude patients without occlusion on arteriography from thrombolytic therapy. To date, the answer cannot be derived from randomized trials or controlled studies. In the present series, little may have been gained with thrombolysis. The majority had a favorable clinical outcome without treatment. The question that remains is the one of arteriolar occlusions, ie, whether such patients have a salvageable penumbra. The answer cannot be given from our angiography series, because neither CT nor any clinical findings was predictive of the outcome. The shortcoming of our study is that we did not perform systematically perfusion CT or perfusion-weighted imaging (PWI) and diffusion-weighted imaging (DWI) MRI before arteriography. These techniques might have been helpful to identify potential candidates for thrombolysis despite normal arteriography. Schellinger et al evaluated DWI and PWI and magnetic resonance angiography (MRA) within 6 hours of stroke onset. 13 Of 8 patients with normal intracranial MRA, 4 had small lacunar, 2 basal ganglia, and 2 presumedly cardioembolic infarcts. A small PWI-DWI mismatch indicating salvageable tissue was observed in only 1 of the 8 patients. Based on pathophysiological considerations, the authors recommended no thrombolysis in patients without vessel occlusion and without PWI-DWI mismatch. They would, however, reluctantly and carefully perform thrombolysis in patients with PWI-DWI mismatch but no vessel occlusion. However, DWI-positive patients may show imaging lesion reversal. 14 Therefore, these recommendations, which are based on pathophysiological considerations, have to be confirmed by randomized controlled trials.
In conclusion, acute stroke patients with normal arteriograms will mostly have a favorable spontaneous recovery. The chances to prevent the few unfavorable outcomes in such patients with thrombolysis may be small, because the ischemic damage is probably irreversibly set already at the time of arteriography. This statement is based on pathophysiological considerations. In the intravenous NINDS trial, a clinical benefit was shown in all subgroups of patients, including patients with small artery disease. However, vessel imaging was not mandatory in the NINDS study. Hopefully, ongoing clinical studies based on DWI and PWI or vessel imaging or both (eg, EPITHET, DIAS, SaTIS, DEFUSE) will improve patient selection and give the answer whether stroke patients with normal vessel status will benefit from thrombolysis. 15 At present, only intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) administered within 3 hours after symptom onset is proven to be effective for the treatment of acute stroke. Based on level I evidence from the NINDS trial and several meta-analyses, rt-PA has been approved in many countries around the world, including the USA, Canada, Australia, and most of Europe. A recent meta-analysis (Marler et al, Lancet 2004, in press) also demonstrates a significant effect of rt-PA in the 3-to 4.5-hour window, albeit that has not changed approval regulations. National and international committees and guidelines name IVT with rt-PA within the 3-hour time window as the first-line treatment of choice. In specific, the European Stroke Initiative (EUSI) states "intravenous rt-PA (0.9 mg/kg, maximum 90 mg), with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes, is the recommended treatment within 3 hours of onset of ischemic stroke (level I)" and "the benefit from the use of intravenous rt-PA for acute ischemic stroke beyond 3 hours after onset of the symptoms is smaller, but present up to 4.5 hours (level I)." 1 The American Stroke Association (ASA) guidelines state: "intravenous rt-PA (0.9 mg/kg, maximum dose 90 mg) is strongly recommended for carefully selected patients who can be treated within 3 hours of onset of ischemic stroke (grade A)." 2 Intraarterial thrombolysis (IAT) has been tested in multiple case series with multiple substances 3 and only one randomized controlled trial positive for pro-urokinase within 3 to 6 hours (level I [ASA] to II [EUSI] because of relatively small sample size) has been published so far, 4 but has not sufficed for FDA approval. The EUSI states: "intraarterial treatment of acute MCA [middle cerebral artery] occlusion in a 6-hour time window using pro-urokinase results in a significantly improved outcome (level II)" and "acute basilar occlusion may be treated with intraarterial therapy in selected centers in an institutional protocol as experimental therapy or within a multicenter clinical trial (level IV)." 1 The ASA states: "IAT is an option for treatment of selected patients with major stroke of Ͻ6-hour duration due to large vessel occlusions of the middle cerebral artery (grade B)" and "importantly, the availability of IAT should generally not preclude the administration of intravenous rt-PA in otherwise eligible patients." 2 It has been an endeavor of many groups to improve the selection of patients for IVT as well as IAT, and to define which patients to treat and which not to treat. Several case series, open trials, or trials with historical controls used MRI criteria, such as the PWI/DWI-mismatch, or arteriographic criteria for IAT, such as presence and site of a vessel occlusion. 5, 6 Larger phase II and III trials addressing these problems are under way (eg, DIAS/DEDAS, DEFUSE, EP-ITHET). 7 In the current issue of Stroke, Arnold et al 8 present a subgroup of their patients (Nϭ28/283) who were arteriographically screened for IAT with urokinase (not prourokinase!) but not treated because of absence of a vessel occlusion. The median baseline NIHSS score was 7, time from symptom onset to arteriography ranged from 1 hour 55 minutes to 5 hours 15 minutes (mean: 3 hours 46 minutes). After 3 months, 21 patients (75%) were independent (modified Rankin Scale score [mRS] Յ 2). However, in 22 patients, infarcts were seen at follow-up imaging. Although no predictors of clinical outcome were identified, the authors concluded that patients with normal early arteriography usually will experience a favorable clinical outcome when not treated and discourage thrombolysis in these patients.
Editorial Comment
From a pathophysiological point of view, it makes sense to treat patients with thrombolytics who have proof of an obliterating thrombus, and to withhold a potentially threatening therapy in patients without a therapeutical substrate. There are only few data about the outcome of patients with patent vessels on early arteriography, 6 and, to my knowledge, outcome data of the PROACT II patients screened with arteriography but not randomized (Nϭ294 142 of these without or with incomplete vessel occlusion) have not been published. Therefore, the observations of Arnold et al are interesting, albeit not surprising. However, with the evidence at hand, the authors should test their hypothesis in a controlled, maybe even randomized, small trial (IAT versus saline in acute stroke patients 3 to 6 hours with thrombolysis in myocardial infarction [TIMI] 2 and 3 flow). Although they will unlikely detect a clinical difference because of small numbers, this would preclude withholding IVT from eligible patients and render a study with a higher evidence level. Granted, this limitation has been discussed.
Nevertheless, it is disturbing that 25% of patients each were either dependent/dead (median baseline NIHSSS of 9, outcome mRS 3 to 6) or had remaining nonincapacitating functional deficits (median baseline NIHSSS of 7, outcome mRS 2). Eight of 28 patients underwent arteriography within 3 hours (20 underwent arteriography within 4.5 hours), 1 had residual symptoms (mRS 2), and 3 were dependent or dead. When assuming a 30-minute delay caused by arteriography, 10 of 28 patients could have received IVT Ͻ3 hours and 24 of 28 patients within 4.5 hours, with the latter not approved but with sound level I evidence in favor of IVT with rt-PA. Mild or improving stroke symptoms are the reason for withholding IVT in one third of patients, and, again, one third of these have a poor outcome. 9 Also, even lacunar infarcts without an arteriographic vessel occlusion may profit from IVT. 10 Furthermore, microcirculatory defects can be overlooked on arteriography. Although recanalization most likely is an independent predictor of good outcome, tissue reperfusion may be even more important in congruence with MI in cardiology. Approved therapies based on level I evidence and recommended by most expert panels and stroke societies should not be discarded in favor of open noncontrolled studies. 2 In 
